Proposed allowable claims for 10/569,076 as suggested by Examiner Allen 6/24/09 and provided to applicant at interview.

1. A fusion polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 4, 6, 7, and 8.

2. A fusion polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 3, 4, 6, 7, and 8.

3. A nucleic acid comprising a nucleotide sequence encoding the fusion polypeptide of claim 1 or 2.

4. A nucleic acid consisting of a nucleotide sequence encoding the fusion polypeptide of claim 1 or 2.

5. A nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 10, 11, 13, 14, and 15.

6. A nucleic acid consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOS: 10, 11, 13, 14, and 15.

7. A vector comprising the nucleic acid of claim 3.

8. A vector comprising the nucleic acid of claim 5 or 6.

9. An isolated host cell comprising the nucleic acid of claim 3.

10. An isolated host cell comprising the vector of claim 7.

11. An isolated host cell comprising the vector of claim 8.

12. A composition comprising the fusion polypeptide of claim 1 or 2 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

13. A composition comprising the nucleic acid of claim 3 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

14. A composition comprising the nucleic acid of claim 5 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

15. A composition comprising the vector of claim 10 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

16. A composition comprising the host cell of claim 7 and a pharmaceutically acceptable carrier, excipient, or adjuvant.

17. A method of treating a patient with a neoplastic disease comprising administering to said patient a fusion polypeptide of SEQ ID NO: 3 or 4 in an amount effective to inhibit tumor growth.

18. A method of treating a patient with a neoplastic disease comprising administering to said patient a fusion polypeptide of SEQ ID NO: 3 or 4 in an amount effective to reduce the size of the tumors in the patient.

19. A method of treating a patient with a neoplastic disease comprising administering to said patient a composition comprising the fusion polypeptide of SEQ ID NO: 3 or 4 and a pharmaceutically acceptable carrier, excipient, or adjuvant in an amount effective to inhibit tumor growth.

20. A method of treating a patient with a neoplastic disease comprising administering to said patient a composition comprising the fusion polypeptide of SEQ ID NO: 3 or 4 and a pharmaceutically acceptable carrier, excipient, or adjuvant in an amount effective to reduce the size of the tumors in the patient.

21. The method according to claim 17, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and
intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.

22. The method according to claim 18, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and
intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.

23. The method according to claim 19, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and
intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.

24. The method according to claim 20, wherein said administering is selected from the group consisting of intravenous, subcutaneous, oral, and
intraperitoneal administration, wherein said oral administration is of a gastrointestinal cleavage resistant formulation.